These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 35728046)

  • 1. Sacituzumab Govitecan-hziy in Breast Cancer.
    Kwapisz D
    Am J Clin Oncol; 2022 Jul; 45(7):279-285. PubMed ID: 35728046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
    N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
    Furlanetto J; Marmé F; Loibl S
    Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
    Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
    Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
    Fenn KM; Kalinsky K
    Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacituzumab Govitecan: First Approval.
    Syed YY
    Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
    Bardia A; Tolaney SM; Punie K; Loirat D; Oliveira M; Kalinsky K; Zelnak A; Aftimos P; Dalenc F; Sardesai S; Hamilton E; Sharma P; Recalde S; Gil EC; Traina T; O'Shaughnessy J; Cortes J; Tsai M; Vahdat L; Diéras V; Carey LA; Rugo HS; Goldenberg DM; Hong Q; Olivo M; Itri LM; Hurvitz SA
    Ann Oncol; 2021 Sep; 32(9):1148-1156. PubMed ID: 34116144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.
    Wahby S; Fashoyin-Aje L; Osgood CL; Cheng J; Fiero MH; Zhang L; Tang S; Hamed SS; Song P; Charlab R; Dorff SE; Ricks TK; Barnett-Ringgold K; Dinin J; Goldberg KB; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1850-1854. PubMed ID: 33168656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 11. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer.
    Kang C
    Target Oncol; 2024 Mar; 19(2):289-296. PubMed ID: 38446351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
    N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
    Bardia A; Rugo HS; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Kalinsky K; Cortés J; Shaughnessy JO; Diéras V; Carey LA; Gianni L; Piccart-Gebhart M; Loibl S; Yoon OK; Pan Y; Hofsess S; Phan SC; Hurvitz SA
    J Clin Oncol; 2024 May; 42(15):1738-1744. PubMed ID: 38422473
    [No Abstract]   [Full Text] [Related]  

  • 14. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 15. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.
    Michaleas S; Moreno Oliver A; Mueller-Berghaus J; Sarac SB; van der Elst ME; Müller-Egert S; Zander H; Enzmann H; Pignatti F
    ESMO Open; 2022 Jun; 7(3):100497. PubMed ID: 35642987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
    Shastry M; Jacob S; Rugo HS; Hamilton E
    Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
    Baek G; Jung L; Duong A; Gralow J
    J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back.
    Rossi V; Turati A; Rosato A; Carpanese D
    Front Immunol; 2024; 15():1447280. PubMed ID: 39211043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of sacituzumab govitecan in solid tumors.
    Veeraballi S; Khawar Z; Aslam HM; Muzaffar M
    J Oncol Pharm Pract; 2022 Oct; 28(7):1617-1623. PubMed ID: 35404158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
    Kalinsky K; Spring L; Yam C; Bhave MA; Ntalla I; Lai C; Sjekloca N; Stwalley B; Stokes M; Taylor A; Nanda R
    Breast Cancer Res Treat; 2024 Nov; 208(1):203-214. PubMed ID: 38904892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.